Posted by Michael Wonder on 10 Nov 2022
Olaparib for adjuvant treatment of patients with high risk, HER2 negative, BRCA positive early breast cancer after chemotherapy
10 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of olaparib in the NHS in England.
Olaparib, when used alone or in combination with endocrine therapy, is not recommended for the adjuvant treatment of adults with HER2 negative high risk early breast cancer that has been treated with neo-adjuvant or adjuvant chemotherapy with germline BRCA1 or 2 mutations.
